ARTICLE | Distillery Therapeutics
Cancer
November 27, 2017 7:03 PM UTC
Cell culture studies suggest inhibiting PDE3A, FYB1, BICC1 or PURPL could help treat liver cancer. In two human liver cancer cell lines, shRNA targeting PDE3A, FYB1, BICC1 or PURPL decreased viability...